Anti-SARS-CoV Envelope (CT)

Anti-SARS-CoV Envelope (CT)

Product No.: S536

[product_table name="All Top" skus="S536"]

- -
- -
Target
SARS E
Product Type
Polyclonal Antibody
Alternate Names
SARS-CoV Envelope Antibody, 4, Envelope small membrane protein, E protein
Isotype
IgG
Applications
ELISA

- -
- -
Select Product Size

Data

Anti-SARS-CoV Envelope (CT) Direct ELISADirect ELISA
- -
- -

Antibody Details

Product Details

Reactive Species
Virus
Host Species
Rabbit
Immunogen
Anti-SARS-CoV Envelope antibody was raised against a peptide corresponding to 11 amino acids near the carboxy terminus of SARS-CoV Envelope protein. The immunogen is located within the last 50 amino acids of SARS-CoV Envelope.
Product Concentration
1.0 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Rabbit Anti-Human Severe Acute Respiratory Syndrome E (SARS E) recognizes Human SARS E. This polyclonal antibody was purified using affinity chromatography.
Background
A coronavirus, SARS (Severe Acute Respiratory Syndrome), was first identified 2002-2003. Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.
PubMed
Research Area
COVID-19
.
Seasonal and Respiratory Infections
.
Viral

References & Citations

1. Marra, M. A. et al. (2003) Science 300:1399 2. Rota, P. A. et al. (2003) Science 300:1394 3. Navas-Nartin, S. R. et al. (2004) J. Neurovirol. 10:75 4. Arbely, E. et al. (2004) J. Mol. Biol. 3414:769
Indirect Elisa Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.